

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

213378Orig1s000

213378Orig2s000

OFFICER/EMPLOYEE LIST

MEMORANDUM

DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION
CENTER FOR DRUG EVALUATION AND RESEARCH

DATE: May 26, 2021

TO: Administrative file for NDA 213378

FROM: Jasmeet (Mona) Kalsi, Regulatory Health Project Manager
Division of Psychiatry, Office of Neuroscience

SUBJECT: Officer/Employee List for NDA 213378

APPLICATION/DRUG: NDA 213378, Lybalvi (olanzapine/Samidorphan) tablets

The following officers or employees of FDA participated in the decision to approve this application and consented to be identified on this list:

Alexander, John J
Amspacher, Valerie
Atrakchi, Aisar H
Avila, Amy
Balimane, Praveen
Bastings, Eric
Bhattaram, Atul
Bouie, Teshara
Chelliah, Mariappan
Chiapperino, Dominic
DeConti, Selena
Dinatale, Miriam
Farchione, Tiffany
Fischer, Bernard
Fuller, Barbara
Golden, Julie
Greeley, George
Grimstein, Manuela
Hart, Leah
Hawkins, Edward
Holmes, Loretta
Hutchins, Shawna
Kolejian, Sevan
Lloyd, Joshua
Mcaninch, Jana

Mellon, Dan
Moukhtara, Aline
Noory, Assadollah
Nguyen, Phuong B
Pinto, Julia
Redwood, Susan
Reissig, Chad J
Roca, Catherine
Sandhu, Sukhminder
Sharretts, John
Southammakosane, Cathy
Stone, Marc
Walker, Shetarra
Wu, Ta-Chen
Xu, Teng
Yancy, Jacqueline
Yang, Peiling
Yang, Yuching
Zhuang, Luning (Ada)

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

JASMEET K KALSI
05/28/2021 11:09:04 AM